Single Enzyme Essential for APC-Deficient Cancer Cell Survival

A newly published study reveals that cancer cells lacking functional APC protein rely on a single metabolic enzyme, ALDH2, for survival, presenting a potential therapeutic target for colorectal cancers associated with this common genetic mutation.

The research, conducted through computational screening and experimental validation, demonstrates that inhibiting ALDH2 in APC-deficient cancer cells leads to a significant reduction in cell proliferation and increased cell death. This effect is not observed to the same extent in cells with intact APC function, highlighting a selective vulnerability in the mutant cells.

ALDH2, an enzyme involved in cellular detoxification, helps manage metabolic stress by processing reactive aldehydes. When inhibited, APC-deficient cells experience an accumulation of reactive oxygen species (ROS), which disrupts cellular homeostasis and activates stress-response pathways including ASK1/JNK signaling.

These pathways are known regulators of apoptosis, and their activation results in a shift in apoptotic regulators — specifically increased BAX and decreased Bcl2 — ultimately driving programmed cell death in the affected cancer cells.

The study suggests that because APC-deficient cells depend on ALDH2 to mitigate oxidative stress, targeting this enzyme could selectively impair tumor growth while sparing normal cells that retain functional APC. This selectivity arises from the differing metabolic dependencies between mutant and normal cells.

APC mutations are among the most prevalent genetic alterations in colorectal cancer, yet direct targeting of the APC protein itself has remained challenging. The identification of ALDH2 as a critical dependency in these mutant cells offers an indirect strategy to exploit this widespread mutation for therapeutic benefit.

While the findings are based on preclinical models, the research provides a mechanistic rationale for further investigation into ALDH2 inhibition as a precision approach for treating APC-driven cancers. The study underscores the importance of context-specific metabolic vulnerabilities in cancer cells.